Primary biliary cirrhosis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 2: | Line 2: | ||
{{Primary biliary cirrhosis}} | {{Primary biliary cirrhosis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{SH}} | ||
==Overview== | ==Overview== | ||
Effective measures for the secondary prevention of primary biliary cirrhosis include follow up with [[liver function tests]] , [[Thyroid function tests|thyroid status]] , [[Endoscopy|upper GI endoscopy]], [[bone mineral density]], [[Fat soluble vitamins|fat-soluble vitamin]] levels, [[ultrasound]] and [[alpha-fetoprotein]] levels to screen for [[hepatocellular carcinoma]] among aged men and patients with underlying [[cirrhosis]]. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
*Effective measures for the secondary prevention of primary biliary cirrhosis include: | *Effective measures for the secondary prevention of primary biliary cirrhosis include:<ref name="pmid16356577">{{cite journal |vauthors=Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R |title=Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome |journal=J. Hepatol. |volume=44 |issue=2 |pages=400–6 |year=2006 |pmid=16356577 |doi=10.1016/j.jhep.2005.10.017 |url=}}</ref><ref name="PouponChazouilleres2006">{{cite journal|last1=Poupon|first1=Raoul|last2=Chazouilleres|first2=Olivier|last3=Corpechot|first3=Christophe|last4=Chrétien|first4=Yves|title=Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis|journal=Hepatology|volume=44|issue=1|year=2006|pages=85–90|issn=0270-9139|doi=10.1002/hep.21229}}</ref><ref name="pmid16911691">{{cite journal |vauthors=Nezu S, Tanaka A, Yasui H, Imamura M, Nakajima H, Ishida H, Takahashi S |title=Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis |journal=J. Gastroenterol. Hepatol. |volume=21 |issue=9 |pages=1448–54 |year=2006 |pmid=16911691 |doi=10.1111/j.1440-1746.2006.04434.x |url=}}</ref> | ||
**Follow up with liver function tests every 3 to 6 months. | **Follow up with [[liver function tests]] every 3 to 6 months. | ||
**Follow up with thyroid status annually. | **Follow up with [[Thyroid function tests|thyroid status]] annually. | ||
**Follow up with upper GI endoscopy to assess for development of varices every 2-3 years. | **Follow up with [[Endoscopy|upper GI endoscopy]] to assess for development of [[varices]] every 2-3 years. | ||
**Follow up with bone mineral density every 2-4 years, depending upon the baseline density and severity of cholestasis. | **Follow up with [[bone mineral density]] every 2-4 years, depending upon the baseline density and severity of [[cholestasis]]. | ||
**Follow up with fat-soluble vitamin levels (Vitamin A,D&K) annually in patients with bilirubin >2mg/dl. | **Follow up with [[Fat soluble vitamins|fat-soluble vitamin]] levels (Vitamin A,D&K) annually in patients with [[bilirubin]] >2mg/dl. | ||
**Follow up with ultrasound and alpha-fetoprotein levels to screen for hepatocellular carcinoma every 6 | **Follow up with [[ultrasound]] and [[alpha-fetoprotein]] levels to screen for [[hepatocellular carcinoma]] every 6 to 12 months among aged men and patients with underlying [[cirrhosis]]. | ||
==References== | ==References== | ||
Revision as of 22:03, 6 February 2018
|
Primary Biliary Cirrhosis Microchapters |
|
Differentiating Primary Biliary Cirrhosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary biliary cirrhosis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Primary biliary cirrhosis secondary prevention |
|
Risk calculators and risk factors for Primary biliary cirrhosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]
Overview
Effective measures for the secondary prevention of primary biliary cirrhosis include follow up with liver function tests , thyroid status , upper GI endoscopy, bone mineral density, fat-soluble vitamin levels, ultrasound and alpha-fetoprotein levels to screen for hepatocellular carcinoma among aged men and patients with underlying cirrhosis.
Secondary Prevention
- Effective measures for the secondary prevention of primary biliary cirrhosis include:[1][2][3]
- Follow up with liver function tests every 3 to 6 months.
- Follow up with thyroid status annually.
- Follow up with upper GI endoscopy to assess for development of varices every 2-3 years.
- Follow up with bone mineral density every 2-4 years, depending upon the baseline density and severity of cholestasis.
- Follow up with fat-soluble vitamin levels (Vitamin A,D&K) annually in patients with bilirubin >2mg/dl.
- Follow up with ultrasound and alpha-fetoprotein levels to screen for hepatocellular carcinoma every 6 to 12 months among aged men and patients with underlying cirrhosis.
References
- ↑ Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R (2006). "Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome". J. Hepatol. 44 (2): 400–6. doi:10.1016/j.jhep.2005.10.017. PMID 16356577.
- ↑ Poupon, Raoul; Chazouilleres, Olivier; Corpechot, Christophe; Chrétien, Yves (2006). "Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis". Hepatology. 44 (1): 85–90. doi:10.1002/hep.21229. ISSN 0270-9139.
- ↑ Nezu S, Tanaka A, Yasui H, Imamura M, Nakajima H, Ishida H, Takahashi S (2006). "Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis". J. Gastroenterol. Hepatol. 21 (9): 1448–54. doi:10.1111/j.1440-1746.2006.04434.x. PMID 16911691.